Rhabdoid Tumor Latest Advances
Find the Latest Research About Rhabdoid Tumor
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2160 publications
Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth.
Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026
CLO26-126: Survival Trends and Prevalence Disparities in Atypical Teratoid Rhabdoid Tumor: A Population Based Univariate vs Multivariate Retrospective Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.
Journal: Neuro-oncology pediatrics
Published: March 27, 2026
Oral malignant melanoma with rhabdoid cell differentiation and myogenic features in a dog.
Journal: The Journal of veterinary medical science
Published: March 11, 2026
Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry images.
Journal: Journal of neuropathology and experimental neurology
Published: March 10, 2026
B7-H3-targeted natural killer cells effectively kill atypical teratoid / rhabdoid tumors and extend survival in orthotopic xenografts.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Atypical Teratoid Rhabdoid Tumor With TTF-1 Expression: A Case Report and Possible Insight Into Its Embryologic Origin.
Journal: Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
Published: February 06, 2026
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.
Journal: Cancer cell
Published: February 01, 2026
SMARCB-1-Positive Rhabdoid Squamous Cell Carcinoma Following Liver Transplant: Systematic Review and Unique Case Report.
Journal: The American Journal of dermatopathology
Published: January 27, 2026
PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2025
Last Updated: 04/28/2026